Want to get a sneak peek at the most exciting oncology advancements? 💥 #ESMO24 is just around the corner, and we've got a special report highlighting the must-see LBAs. Get exclusive insights into potential treatment paradigm shifts across various tumor types featuring Alex Spira, MD, PhD, FACP, FASCO of Virginia Cancer Specialists, P.C., Neal Shore of Carolina Urologic Research Center, Giuseppe Curigliano, Robert M. Jotte, M.D. Ph.D., and more experts from Dana-Farber Cancer Institute, The US Oncology Network, ESMO - European Society for Medical Oncology! Don't miss out! Click here to access the full report: https://lnkd.in/ekn6h5Z4
Targeted Oncology
Online Audio and Video Media
Cranbury Township, New Jersey 54,626 followers
The Community Resource in Targeted Therapies
About us
TargetedOnc.com provides content focused on next generation therapeutics and their molecular targets. As the field of oncology continues to trend toward systemic biology and molecular aberrations, the challenge facing many oncologists is staying recent and up-to-date with the future of cancer therapeutics. TargetedOnc.com focuses on the next stage of cancer development, focusing on cutting edge therapies and their biological targets. Content is organized by therapy type, target, peer-reviewed content, and conference coverage.
- Website
-
http://targetedonc.com
External link for Targeted Oncology
- Industry
- Online Audio and Video Media
- Company size
- 2-10 employees
- Headquarters
- Cranbury Township, New Jersey
- Type
- Public Company
- Specialties
- Oncology, Healthcare Communications, Healthcare, Cancer Research, Targeted Therapies, Community Oncology, Cancer, Cancer Treatment, and Oncologists
Locations
-
Primary
2 Clarke Dr
Cranbury Township, New Jersey, US
Employees at Targeted Oncology
Updates
-
Trastuzumab-strf, a trastuzumab biosimilar, at 420 mg has been approved by the #FDA for the treatment of HER2-overexpressing cancers, including metastatic breast and gastric/gastroesophageal junction cancers. https://lnkd.in/e_cg9vpp
-
WATCH: Christos Vaklavas, MD, discusses the results of the TROPION-Breast01 trial of datopotamab deruxtecan in patients with metastatic breast cancer. #bcsm | Huntsman Cancer Institute https://lnkd.in/eMNM_-5c
PFS Provides Rationale for Dato-DXd vs Chemo in HR+, HER2– Breast Cancer
targetedonc.com
-
“We have made strides in immune-based strategies in [#SCLC], and it gives us hope that we are going to have better opportunities to use the new classes of drugs,” -David R. Spigel, MD. Sarah Cannon Research Institute https://lnkd.in/eeT_N5-p
-
#BREAKINGNEWS: #FDA approves perioperative #nivolumab in resectable #NSCLC. Read more HERE: https://lnkd.in/ejXVvytZ
FDA Approves Perioperative Nivolumab in Resectable NSCLC
targetedonc.com
-
Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with #DLBCL. #lymsm https://lnkd.in/eBdTAvBV
-
In August 2024, the #FDA made several significant advances in #oncology, impacting a range of cancers. Read up on the developments HERE: https://lnkd.in/e76VPEGj
September 2024 FDA Roundup: Key Decisions Drive Oncology Forward
targetedonc.com
-
In an interview with Targeted Oncology, Chunhui Han, PhD, discussed the use of Ga 68 PSMA-11 for the imaging of metastatic sites in patients with prostate cancer. #pcsm | City of Hope https://lnkd.in/exqPxDmh
Enhancing Prostate Cancer Radiotherapy Precision With Gallium 68 PSMA-11
targetedonc.com
-
Axatilimab in Refractory/Recurrent cGVHD: A Promising Later-Line Option | Dana-Farber Cancer Institute, Mass General Brigham https://lnkd.in/ePw6MzRP
Axatilimab in Refractory/Recurrent cGVHD: A Promising Later-Line Option
targetedonc.com
-
ICYMI: Stay on top of what your peers are saying with our most recent publication of Peers & Perspectives in Oncology! https://ow.ly/vH1l50Ts0gU